secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001437749-25-018000
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals reports Q1 net loss of $5.5M, advances NDA filings and HOPE clinic acquisitions
--------------------------------------------------------------------------------

- Net loss narrowed to $5.5M for Q1 2025 from $6.5M in Q1 2024; operating loss $3.8M vs $6.0M.
- Cash & cash equivalents $5.5M at March 31, 2025; company expects sufficient runway through end of 2025.
- NDA for NRX-100 (IV ketamine) filing on track for Q2 2025; FDA waived $4.3M filing fee; U.S. patent application filed.
- HOPE Therapeutics signed $7.8M debt term sheet with Universal Capital and $2.5M strategic investment for clinic acquisitions; initial clinics have ~$15M pro-forma revenue.
- NRX-101 NDA submission for suicidal bipolar depression on track for 2025; anticipates PDUFA before year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925018000/0001437749-25-018000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925018000/nrxp20250521_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-018000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer